Andrew von Eschenbach
Directeur/Membre du Conseil chez TRISALUS LIFE SCIENCES, INC.
Fortune : 462 059 $ au 30/06/2024
Profil
Andrew C.
von Eschenbach founded Samaritan Health Initiatives, Inc. in 2010, where he is working as President from 2010.
Dr. von Eschenbach also currently works at Bausch & Lomb, Inc., as Independent Director, Viamet Pharmaceuticals, Inc., as Director from 2011, Viamet Pharmaceuticals Corp., as Independent Director from 2011, and various other companies.
Dr. von Eschenbach also formerly worked at Elan Corp.
Plc, as Independent Non-Executive Director from 2011 to 2014, Lineage Cell Therapeutics, Inc., as Independent Director from 2012 to 2014, Radius Health, Inc., as Independent Director from 2021 to 2022, and various other companies.
Dr. von Eschenbach received his undergraduate degree from St. Joseph's University and doctorate degree from Georgetown University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/05/2023 | 25 357 ( 0,01% ) | 368 184 $ | 30/06/2024 | |
CELULARITY INC. CLASS A
0,14% | 14/06/2023 | 29 992 ( 0,14% ) | 93 875 $ | 30/06/2024 |
| 03/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Andrew von Eschenbach
| Sociétés | Poste | Début |
|---|---|---|
| BAUSCH + LOMB CORPORATION | Directeur/Membre du Conseil | 01/04/2022 |
| TRISALUS LIFE SCIENCES, INC. | Directeur/Membre du Conseil | 10/08/2023 |
Focused Ultrasound Foundation
 Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Focused Ultrasound Foundation is an early-sage company, which engages in the provision of non-invasive therapeutic technology. It focuses on cardiovascular, endocrine disorders, gastrointestinal, musculoskeletal, neurological, oncological, urological, and women''s health sectors. The company was founded by Neal F. Kassell and is headquartered in Charlottesville, VA. | Directeur/Membre du Conseil | 09/08/2010 |
| Samaritan Health Initiatives, Inc. | Fondateur | 01/01/2010 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Directeur/Membre du Conseil | - |
| Reagan-udall Foundation | Directeur/Membre du Conseil | 01/12/2018 |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 01/11/2019 |
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Andrew von Eschenbach
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Andrew von Eschenbach
| St. Joseph's University | Undergraduate Degree |
| Georgetown University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| ONCOCYTE CORPORATION | Health Technology |
| BAUSCH HEALTH COMPANIES INC. | Health Technology |
| CELULARITY INC. | Commercial Services |
| BAUSCH + LOMB CORPORATION | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 23 |
|---|---|
Focused Ultrasound Foundation
Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Focused Ultrasound Foundation is an early-sage company, which engages in the provision of non-invasive therapeutic technology. It focuses on cardiovascular, endocrine disorders, gastrointestinal, musculoskeletal, neurological, oncological, urological, and women''s health sectors. The company was founded by Neal F. Kassell and is headquartered in Charlottesville, VA. | Commercial Services |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
National Comprehensive Cancer Network, Inc.
 National Comprehensive Cancer Network, Inc. Miscellaneous Commercial ServicesCommercial Services National Comprehensive Cancer Network, Inc. provides research and development services to fight against cancer. The organization develops resources that present information to the numerous stakeholders in the health care delivery system. The company was founded in 1995 and is headquartered in Fort Washington, PA. | Commercial Services |
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Banyan Biomarkers, Inc.
 Banyan Biomarkers, Inc. Medical/Nursing ServicesHealth Services Banyan Biomarkers, Inc. engages in the commercialization of vitro diagnostic tests for the detection of brain injury and neurological diseases. It develops blood test to accurately and quickly diagnose traumatic brain injury. The company was founded by Nancy Denslow, Ronald L. Hayes, and Kevin Wang in 2002 and is headquartered in San Diego, CA. | Health Services |
HistoSonics, Inc.
 HistoSonics, Inc. Medical SpecialtiesHealth Technology HistoSonics, Inc. develops medical devices. The company was founded by Christine Gibbons, Jim Bertolina, Zhen Xu, William Robert, Hall Timothy, J. Brian Fowlkes, Thomas W. Davison, and Charles Cain in November 2009 and is headquartered in Ann Arbor, MI. | Health Technology |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Manhattan Institute For Policy Research, Inc.
 Manhattan Institute For Policy Research, Inc. Miscellaneous Commercial ServicesCommercial Services Manhattan Institute For Policy Research, Inc. develops and disseminate new ideas for greater economic choice and individual responsibility. It focuses on economic growth, education, energy and environment, health care, legal reform, public sector, race and urban policy. The company was founded by Antony Fisher and William J. Casey in 1977 and is headquartered in New York, NY. | Commercial Services |
| National Comprehensive Cancer Network Foundation | |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
| Samaritan Health Initiatives, Inc. | |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
Cypher Genomics, Inc.
 Cypher Genomics, Inc. Information Technology ServicesTechnology Services Cypher Genomics, Inc. provides automated human genome interpretation software solutions. It offers molecular diagnostics, drug development, and science and technology. The company was founded by Ashley Van Zeeland and Ali Torkamani in 2011 and is headquartered in San Diego, CA. | Technology Services |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Health Technology |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Commercial Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Reagan-udall Foundation | |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
